Outlook Therapeutics, Inc.
About Outlook Therapeutics, Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.4M
- Net income
- -$62.4M
- Total assets
- $18.6M
- Market cap
- $115.4M
- Gross margin
- 4.0%
- Operating margin
- -4744.3%
- Net margin
- -4416.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.4M
- Cost of revenue
- $1.4M
- Gross profit
- $57.2K
- Operating expenses
- $67.1M
- Operating income
- -$67.1M
- Income tax
- -$1.6M
- Net income
- -$62.4M
- EPS (basic)
- $-1.79
- EPS (diluted)
- $-1.79
Balance sheet
- Total assets
- $18.6M
- Current assets
- $17.4M
- Total liabilities
- $50.8M
- Current liabilities
- $45.8M
- Shareholders’ equity
- -$32.2M
Cash flow
- Operating cash flow
- -$51.8M
- Investing cash flow
- $6.8M
- Financing cash flow
- $45.0M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $115.4M
- EPS (diluted)
- $-1.79
- Shares outstanding
- 160.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 13, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $62.4M in FY2025.
- Revenue grew 251% from FY2021 to FY2025.
- Gross margin of 4.0%, net margin -4416.2%.
- Trading 76% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Outlook Therapeutics, Inc..
Write a review
News about Outlook Therapeutics, Inc.
News & sentiment via Polygon.io
